Sinovac Life Sciences Co., Ltd.
Clinical trials sponsored by Sinovac Life Sciences Co., Ltd., explained in plain language.
A Chinese biopharmaceutical company focused on vaccines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New pneumonia vaccine trial aims to shield 3,000 kids from deadly infection
⭐️ VACCINE ⭐️ Recruiting nowThis Phase 3 trial is testing a new 13-valent pneumococcal conjugate vaccine (PCV13) in over 3,000 healthy infants and children aged 6 weeks to 5 years. The goal is to see if the vaccine is safe and triggers a strong immune response compared to an existing vaccine. If it works, i…
Phase: PHASE3 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:00 UTC
-
New vaccine aims to shield toddlers from 24 pneumonia strains
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a new vaccine (PCV24) designed to protect children aged 2 to 23 months against 24 types of pneumococcal bacteria, which can cause serious infections like pneumonia and meningitis. Around 180 healthy children will receive either the new vaccine or an existing one …
Phase: PHASE1 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:00 UTC
-
New 24-Valent vaccine aims to shield children from more pneumonia strains
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a new vaccine called PCV24 in 420 healthy children aged 2 months to 5 years. The vaccine targets 24 types of pneumococcal bacteria, which can cause pneumonia, meningitis, and ear infections. Researchers will compare it to an existing vaccine to see if it is safe …
Phase: PHASE2 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:06 UTC